Celleron Therapeutics
An innovative oncology healthcare company
The future of cancer therapy lies in the ability to target new medicines to responsive tumours. Celleron Therapeutics is dedicated to the goal of developing novel targeted cancer medicines to treat stratified patient groups. The company has a portfolio of unique cancer therapies underpinned by a proprietary biomarker technology. All of which are the result of many years experience in cancer research, drug development and clinical practice.
> Read more
Highly experienced management team
Professor Nick La Thangue MA BSc MSc PhD FRSE FMedSci (Founding Director)
Nick has extensive commercial experience derived from the biotechnology sector of M&A, IPO and corporate financing. Currently he holds the Chair of Cancer Biology at the University of Oxford and is a Fellow at Linacre College.
> Read more
Professor David Kerr CBE MA MD DSc FRCP (Glas & Lon) FRCGP (Hon) FMedSci (Founding Director)
David has an international reputation for treatment of and research into colorectal cancer. He holds the Chair of Cancer Therapeutics at Oxford University is Chief Research Advisor to the Qatar Foundation and is a Fellow of Corpus Christi at the University of Oxford.
> Read more
> Read more
Professor Nick La Thangue MA BSc MSc PhD FRSE FMedSci (Founding Director)
Nick has extensive commercial experience derived from the biotechnology sector of M&A, IPO and corporate financing. Currently he holds the Chair of Cancer Biology at the University of Oxford and is a Fellow at Linacre College.
> Read more
Professor David Kerr CBE MA MD DSc FRCP (Glas & Lon) FRCGP (Hon) FMedSci (Founding Director)
David has an international reputation for treatment of and research into colorectal cancer. He holds the Chair of Cancer Therapeutics at Oxford University is Chief Research Advisor to the Qatar Foundation and is a Fellow of Corpus Christi at the University of Oxford.
> Read more
